The Chinese National Medical Products Administration (NMPA) has approved AstraZeneca’s Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of COPD, the company said. AstraZeneca’s Breztri Aerosphere budesonide/glycopyrronium/formoterol fumarate MDI was approved for the treatment of COPD by the NMPA in December 2019.
In June 2019, Bevespi Aerosphere was approved for the treatment of COPD in Japan. The inhaler has been approved for the treatment of COPD in the US since 2016 and in the EU since December 2018 and is also approved in Canada and Australia.
AstraZeneca Executive VP, BioPharmaceuticals R&D, Mene Pangalos commented, “Chronic obstructive pulmonary disease affects almost 100 million people in China and presents a significant patient and public health burden. The use of maintenance combination therapies in China is increasing year-on-year and the approval of Bevespi Aerosphere offers an important new treatment and choice of inhaler for patients, particularly those with limited lung function and advanced age who may benefit from using a pressurized metered-dose inhaler.
Read the AstraZeneca press release.
